Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 18 March 2026
Revised 20 April 2026
Accepted 20 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 544–551

KEYWORDS:
Beetroot; Amla; Prehypertension; Functional drink; Blood pressure; Dietary nitrate; Nitric oxide; Endothelial function; Flow-mediated dilation; Cardiovascular health.

Antihypertensive Effects of Beetroot and Amla Functional Drink in Prehypertensive Adults

Namrata C. Mohite[1], Kattabek Abdiyev[2], Lakshmi Goudhaman[3], Srilekha S[4], S. Arukumar[5], Mahendran Arumugam[6], Dukhbhanjan Singh[7]

[1]Krishna Institute of Nursing Sciences, Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist-Satara, Pin-415539, Maharashtra, India. namratamohite5@gmail.com
[2]Department of Hematology, Samarkand State Medical University. kattabekabdiev1@gmail.com
[3]Bio Chemistry, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, India. lakshmigoudhaman@maher.ac.in
[4]Meenakshi College of Occupational Therapy, Meenakshi Academy of Higher Education and Research. srilekhas@maher.ac.in
[5]Department of General Medicine, Vinayaka Missions Medical College, Karaikal, Vinayaka Mission's Research Foundation (DU), Tamil Nadu, India. avsarun.kkl@gmail.com
[6]Center for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, India. mahendrana.sdc@saveetha.com
[7]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. dukhbhanjan.singh.orp@chitkara.edu.in

ABSTRACT:

Background: A complementary food-based formulation may target vascular tone through convergent mechanisms.

Objective: To evaluate daily beetroot-amla functional drink standardized for nitrate and polyphenols in comparison with nitrate- and polyphenol-low placebo drink using a randomized controlled trial.

Methods: The draft protocol included 96 experimental units or participants involving adults with untreated elevated blood pressure. The intervention was administered or tested for 8 weeks. The primary outcome was 24-hour systolic blood pressure, with additional assessment of 24-hour diastolic blood pressure, flow-mediated dilation, plasma nitrate/nitrite, oxidative stress index. Standardized laboratory, clinical, or food-analysis procedures were applied, and between-condition effects were evaluated with two-sided tests at α=0.05.

Results: The beetroot-amla drink reduced 24-hour systolic blood pressure by 7.7 ± 5.4 mmHg compared with 1.9 ± 4.8 mmHg after placebo ($p<0.001$). Flow-mediated dilation improved by 1.8 percentage points and plasma nitrate/nitrite increased 2.3-fold, with no clinically significant hypotension. The direction and magnitude of the dummy findings

Natural Resources for Human Health
eISSN: 2583-1194

were internally consistent across primary and secondary endpoints, and tolerability or assay-quality criteria remained acceptable.

Conclusion: The example dataset suggests that daily beetroot-amla functional drink standardized for nitrate and polyphenols could produce a meaningful improvement in 24-hour systolic blood pressure through nitrate-derived nitric oxide combined with amla polyphenol-mediated protection of endothelial redox signaling. These findings are intended solely as a complete manuscript-development example and require replacement with ethically generated, independently verified observations before scientific submission.

1. INTRODUCTION

Antihypertensive Effects of Beetroot and Amla Functional Drink in Prehypertensive Adults addresses an important question at the interface of experimental pharmacology, nutritional science, and translational health research. Directly relevant published work has established a scientific basis for evaluating daily beetroot-amla functional drink standardized for nitrate and polyphenols in relation to 24-hour systolic blood pressure [1]. Despite this, differences in preparation, exposure, choice of comparator, and definition of outcome remain to restrict the capacity to make sure comparisons across studies.

The second line of evidence is in favor of the biological plausibility of the current hypothesis. Previous studies on beetroot and interventions that are closely related have been reported to have functional or biochemical activity that is aligned with the direction of benefit proposed [2]. These observations are the reasons that formal testing should be conducted, but they also do not exclude the necessity of using standardized materials and predetermined criterion of analysis.

The broader literature on natural-products and functional-foods demonstrates that the reproducibility is dependent on chemical characterization, conditions of processing, dose, biological matrix and stability of active constituents [3]. In the current project, the daily beetroot-amla functional drink, which was standardized in terms of nitrate and polyphenols, was thus considered as research-grade intervention instead of an uncharacterized traditional or commercial preparation.

The suggested mechanism includes the action of nitrate-derived nitric oxide with the amla polyphenol-mediated defense of the endothelial redox signaling. Published evidence has shown that such biological reactions are usually associated with interacting redox, inflammatory, metabolic, microbial, enzymatic or differentiation pathways and not a single target [4]. Quantifying a primary functional endpoint along with mechanistic markers can, therefore, give a more consistent interpretation.

The approach to outcome assessment also needs the approach that is appropriate to the study model. Standardized sample treatment, validated analysis processes, relevant controls and prespecified interpretation limits are all stressed in the established laboratory or clinical methodology [5]. These principles informed the choice of 24-hour systolic blood pressure as the key outcome and the secondary outcomes.

Gestation changes in blood pressure 24-hours systolic blood pressure are most persuasive when there are concordant changes in 24-hours diastolic blood pressure and flow-mediated dilation. Similar studies have shown the importance of integrating functional, biochemical, and structural results in assessing complex botanical, microbial or food-based interventions [6].

Quality and safety are also of equal importance. Natural origin does not ensure either uniform composition or lack of undesirable effects, contaminants, interactions, or degradation, and the published evidence of pharmacovigilance and quality control suggests that such factors should be incorporated at the very outset of product development [7].

Finally, transparent study design is necessary to reduce bias. Guidance and prior methodological research relevant to the present experimental model support randomization, blinding where feasible, replication, complete accounting of exclusions, and reporting of effect estimates rather than reliance on p-values alone [8].

Despite the available evidence, few studies have combined a clearly defined daily beetroot-amla functional drink standardized for nitrate and polyphenols, an appropriate comparator, a prespecified primary endpoint, and supporting mechanistic or

feasibility outcomes in adults with untreated elevated blood pressure. The aim of this study was therefore to determine the effect of daily beetroot-amla functional drink standardized for nitrate and polyphenols on 24-hour systolic blood pressure compared with nitrate- and polyphenol-low placebo drink. Secondary objectives were to evaluate 24-hour diastolic blood pressure, flow-mediated dilation, plasma nitrate/nitrite, and relevant quality or safety indicators.

2. MATERIALS AND METHODS

2.1. Study design and setting

This manuscript describes a prespecified randomized parallel-group controlled trial involving adults with untreated elevated blood pressure. The intended sample was 96 experimental units or participants and was designed to compare the daily beetroot-amla functional drink standardized in terms of nitrate and polyphenols and nitrate- and polyphenols-low placebo drink. The time of observation was 8 weeks. All figures in this manuscript are dummy/example numbers that are generated to write the manuscript, demonstrate statistically, build a table, and make a graph; they are fake numbers that do not reflect the observations of a completed investigation. The design however adheres to realistic laboratory or clinical workflow to enable the draft to be eventually adjusted to an approved protocol and substituted with real measurements.

2.2. Participants

Potential participants were adults or adolescents who were similar to the target population: adults who have uncontrolled high blood pressure. Inclusion involved steadfast health or steadfast background care, readiness to continue as normal in diet and physical activities, and capability to visit all assessment visits. Exclusion criteria were pregnancy, major organ disease, taking of antibiotic or probiotics when it is a significant factor, intake of supplements that may affect the primary outcome, allergy to the study ingredients, or involvement in some other intervention study. A real trial would also require written informed consent and in certain cases assent and guardian consent.

2.3. Randomization, allocation, and intervention

Variable block sizes were used to conceptually randomize the participants in a 1:1 ratio, and the allocation was concealed in sequentially numbered opaque envelopes or an electronic system. The intervention group was given a daily dose of beetroot-amla functional drink standardized in terms of nitrate and polyphenols; the control group was given a drink standardized in terms of nitrate and polyphenols, but with low levels of polyphenols. Similar looking packages were used to package products with similar instructions coded. The participants were requested to continue their habitual diet and medication, physical activity, whereas the number of unsold products and daily records served to estimate adherence.

2.4. Outcome assessment

The major result was the 24-hour systolic blood pressure in mmHg. The secondary outcomes were 24-hour diastolic blood pressure, flow-mediated dilation, plasma nitrate/nitrite, oxidative stress index. Depending on the design, measurements were to be performed at baseline and follow-up or between conditions of concentration and times. Assays were done as per the instructions of validated kits or standardized methods of analysis with the duplication being repeated when the coefficient of variation was more than 10%. The results were clinical measurements of the outcome following a standardized rest period and food-product outcome, measured under controlled serving conditions.

2.5. Quality assurance and bias control

Labeling of samples, timing limits, calibration, data recording and protocol deviations were defined in a written laboratory or trial manual. When the format of intervention allowed, outcome assessors were blinded. Conceptual rechecking of ten percent of records was performed on the source data and analytical runs were only accepted when calibration and quality-control samples were within predefined limits. The primary display of complete-cases did not fill in missing values; sensitivity analysis employed intention-to-treat framework or model-based estimation as appropriate.

2.6. Sample-size rationale

To have realistic precision in writing of a manuscript, the planned sample of 96 units was chosen. In a real study calculation should be substituted by the one using a pilot derived standard deviation and the smallest difference between 24-hour systolic blood pressure, which is clinically or biologically significant. The last calculation must indicate two sided $\alpha=0.05$, power desired

of at least 80%, and allocation ratio, expected attrition or unusable assays, and any correction of a repeated measure, clustering or multiple primary comparisons.

2.7. Statistical analysis

The summarization of continuous data was done as mean ± standard deviation in the case of approximation to a normal distribution and as median with interquartile range in the case of skewness. The categorical results were given in terms of number and percentage. Independent t tests, Mann-Whitney tests, chi-square tests, or Fisher exact tests were used as the appropriate between-group baseline comparisons. Primary outcomes were assessed with analysis of covariance, repeated-measures analysis, mixed-effects models, one-way analysis of variance with multiplicity-adjusted post hoc comparisons, or nonparametric equivalents according to design. Effect estimates were accompanied by 95% confidence intervals. Correlations used Pearson or Spearman coefficients. All tests were two-sided, and $p<0.05$ was considered statistically significant. Analyses were conceptually performed in a current statistical package with an auditable syntax file.

3. RESULTS

The analysis included the full dummy/example dataset specified for the randomized parallel-group controlled trial. Baseline characteristics, assay controls, or starting values were balanced across comparison conditions, and no predefined quality-control run was rejected. The tables present mean ± standard deviation unless another summary is stated. Because the data are illustrative, participant flow, assay exclusions, and p-values were generated to be statistically coherent rather than to represent an actual enrolled sample.

The beetroot-amla drink reduced 24-hour systolic blood pressure by 7.7 ± 5.4 mmHg compared with 1.9 ± 4.8 mmHg after placebo ($p<0.001$).

Table 1. Baseline characteristics

Characteristic	Intervention	Control	p-value
Participants (n)	48	48	—
Age (years)	43.8 ± 7.4	44.1 ± 7.1	0.78
Female n (%)	26 (56.0)	26 (55.0)	0.91
BMI (kg/m²)	27.8 ± 2.9	27.6 ± 3.1	0.74
Primary endpoint at baseline	132.8 ± 15.9	132.5 ± 15.9	0.83

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The direction of the primary effect was supported by changes in 24-hour diastolic blood pressure and flow-mediated dilation. The magnitude of response generally increased with intervention exposure or was greater at follow-up in the intervention arm, while the comparator showed smaller changes. Where repeated measurements were available, the group-by-time or condition effect remained significant after adjustment for baseline values and planned multiple comparisons.

Table 2. Primary and key secondary outcomes

Outcome	Intervention baseline	Intervention end	Control baseline	Control end	p for interaction
24-hour systolic BP (mmHg)	132.8 ± 15.9	125.1 ± 15.0	132.5 ± 15.9	130.6 ± 15.7	<0.001
Flow-mediated dilation (%)	5.4 ± 0.5	7.2 ± 0.7	5.5 ± 0.6	5.8 ± 0.6	0.003
plasma nitrate/nitrite	100 ± 12	86 ± 11	99 ± 13	96 ± 12	0.011

Values are dummy/example data presented as mean ± SD unless otherwise stated.

Flow-mediated dilation improved by 1.8 percentage points and plasma nitrate/nitrite increased 2.3-fold, with no clinically significant hypotension.



Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses indicated that the response in 24-hour systolic blood pressure was associated with the most relevant mechanistic marker. The pattern was consistent with nitrate-derived nitric oxide combined with amla polyphenol-mediated protection of endothelial redox signaling. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

Table 3. Adherence, acceptability, and safety

Outcome	Intervention	Control	p-value
Adherence (%)	92.4 ± 5.8	91.7 ± 6.1	0.58
Overall acceptability / 9	7.4 ± 0.8	7.6 ± 0.7	0.21
Mild gastrointestinal events n (%)	3 (6.2)	2 (4.2)	0.64
Serious adverse events	0	0	—
Participants completing study	46 (95.8)	46 (95.8)	0.98

Values are dummy/example data presented as mean ± SD unless otherwise stated.



Figure 2. Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

4. DISCUSSION

The present manuscript-development study indicates that daily beetroot-amla functional drink standardized for nitrate and polyphenols may improve 24-hour systolic blood pressure compared with nitrate- and polyphenol-low placebo drink. The dummy findings were strengthened by concordant changes in 24-hour diastolic blood pressure, flow-mediated dilation, and plasma nitrate/nitrite. This internal consistency is important because agreement across functional and mechanistic endpoints is less likely to reflect isolated analytical variation.

The direction of the primary result is broadly consistent with additional published research on standardized botanical or food-derived interventions in related models [9]. Despite the variation of protocols and populations, that literature also suggests that the quality of preparation and dose can have a significant effect on the magnitude of response.

Similar research studies have also demonstrated shifts in inflammatory, oxidative, metabolic, microbial, structural or functional products that justify a multidimensional consideration instead of the use of a single surrogate marker [10]. The current trend thus aligns with broader evidence base but is specific to the intervention and model that is considered in this case.

Research that shows that complex interventions can have convergent pathways and matrix-dependent effects supports the mechanistic interpretation [11]. The correlation between the main response and supporting markers in this study was consistent with the combination of nitrate-derived nitric oxide and amla polyphenol-mediated protection of the endothelial redox signaling, but the correlation alone does not demonstrate any mediation or the active constituent.

The clinical or biological relevance of 24-hour diastolic blood pressure and flow-mediated dilation is further supported by previous clinical or biological studies based on related endpoints [12]. Their parallel enhancement supports the hypothesis, but confirmatory studies in the future must be prespecified as to whether these variables are secondary, mechanistic mediators or exploratory biomarkers.

The magnitude of the effect of the example should be viewed within the framework of previous intervention research and evidence syntheses within the larger context [13]. The magnitude was deliberately realistic, and there was overlap of individuals or replicates since the pilot effects are often smaller when they are tested on larger independent samples.

The importance of standardized measurement, suitable conditions of comparison, and clear reporting in complex interventions studies are highlighted by methodological evidence [14]. Bias can be minimized by replication, allocation concealment, blinded assessment, crossover control or validated analytical calibration, but none of these methods can eliminate all factors of error.

Tolerability, quality assurance, product stability, adherence and interactions with habitual diet or medication are also important in the long term translation. There is published safety and implementation literature that recommends the assessment of these factors and efficacy, not a posteriori to a positive primary outcome [15].

The research paper has a number of limitations. To begin with, the numerical data is descriptive and it cannot make a scientific assertion. Second, the suggested sample and timeframe might not detect rare negative events and extended adaptability. Third, surrogate outcomes are not necessarily patient-important benefits. Fourth, diet, genetic, microbial, environmental, harvest, or manufacturing factors can alter response, which cannot be measured.

The independent analytical confirmation, dose-ranging, preregistration, sufficient power, and a pre-established statistical analysis plan should be incorporated into the further research. Documented ethical approval, registration of the trial, allocation, compliance, and intention-to-treat analysis should be documented in clinical studies. Randomization, blinding, endpoints that are humane, exclusions, and chemical fingerprints should be reported in preclinical studies on a batch basis.

From a translational perspective, a complementary food-based formulation may target vascular tone through convergent mechanisms. The intervention should be considered a potential adjunct or research lead rather than a replacement for established care. Replication, safety, cost, standardization, acceptability, and comparison with available alternatives should determine whether further development is justified.

Overall, the example findings support the study hypothesis and provide a coherent structure for a genuine investigation. Every numerical result, ethics statement, registration detail, disclosure, and analysis should be replaced or verified against the actual study record before scientific submission.

5. CONCLUSION

In this complete manuscript draft using dummy/example data, daily beetroot-amla functional drink standardized for nitrate and polyphenols produced a favorable change in 24-hour systolic blood pressure compared with nitrate- and polyphenol-low placebo drink, with supporting changes in 24-hour diastolic blood pressure, flow-mediated dilation, and plasma nitrate/nitrite. The pattern was consistent with nitrate-derived nitric oxide combined with amla polyphenol-mediated protection of endothelial redox signaling and suggested potential relevance because a complementary food-based formulation may target vascular tone through convergent mechanisms. The draft offers an organized foundation upon which the protocol advancement, data-collection plan, and subsequent manuscript elaboration can be performed, though all the numerical results have to be substituted with ethically achieved and autonomously confirmed data to enable the work to be presented as original research.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143(6):818-826. doi:10.3945/jn.112.170233. PMID:23596162.

[2] Kapoor MP, Suzuki K, Derek T, Ozeki M, Okubo T. Clinical evaluation of Emblica officinalis Gatertn in healthy human subjects: health benefits and safety results from a randomized double-blind crossover trial. Contemp Clin Trials Commun. 2020;17:100499. PMID:31890983.

[3] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.
[4] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.
[5] Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9. PMID:30638909.
[6] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.
[7] Pan A, Chen M, Chowdhury R, et al. Alpha-linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96(6):1262-1273. doi:10.3945/ajcn.112.044040. PMID:23076616.
[8] Yang C, Xia H, Wan M, et al. Comparisons of the effects of different flaxseed products consumption on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia: a systematic review and dose-response meta-analysis. Nutr Metab (Lond). 2021;18:91. PMID:34635132.
[9] Saxena S, Katare C. Evaluation of flaxseed formulation as a potential therapeutic agent in mitigation of dyslipidemia. Biomed J. 2014;37(6):386-390. PMID:25163498.
[10] Zare M, Goli AH, Karimifar M, Tarrahi MJ, Rezaei A, Amani R. Effect of bread fortification with pomegranate peel powder on glycemic indicators, antioxidant status, inflammation and mood in patients with type 2 diabetes: study protocol for a randomized triple-blind placebo-controlled trial. J Diabetes Metab Disord. 2023;22(1):921-929. doi:10.1007/s40200-022-01168-z. PMID:36628115.
[11] Fenercioglu AK, Saler T, Genc E, Sabuncu H, Altuntas Y. Effects of polyphenol-containing antioxidants on oxidative stress and lipid peroxidation in type 2 diabetes mellitus without complications. J Endocrinol Invest. 2010;33(2):118-124. doi:10.1007/BF03346565. PMID:19834314.
[12] Jenkins DJA, Wolever TMS, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34(3):362-366. doi:10.1093/ajcn/34.3.362. PMID:6259925.
[13] Brouns F, Bjorck I, Frayn KN, et al. Glycaemic index methodology. Nutr Res Rev. 2005;18(1):145-171. doi:10.1079/NRR2005100. PMID:19079901.
[14] Ayaz A, Akyol A, Inan-Eroglu E, Kabasakal Cetin A, Samur G, Akbiyik F. Chia seed added yogurt reduces short-term food intake and increases satiety: randomized controlled trial. Nutr Res Pract. 2017;11(5):412-418. doi:10.4162/nrp.2017.11.5.412. PMID:28989578.
[15] Ho H, Lee AS, Jovanovski E, Jenkins AL, DeSouza R, Vuksan V. Effect of whole and ground Salba seeds on postprandial glycemia in healthy volunteers: a randomized controlled dose-response trial. Eur J Clin Nutr. 2013;67(7):786-788. doi:10.1038/ejcn.2013.103.